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Abstract
Purpose of review The purpose of this review is to assess the evidence behind treatment
regimens for cerebellar ataxias occurring in the context of systemic disease. We will
address systemic conditions which are associated with specific involvement of the cere-
bellum (rather than widespread nervous system involvement) and those conditions for
which some degree of evidence of treatment response exists.
Recent findings We have divided systemic disorders affecting the cerebellum into systemic
immunological disorders, endocrine and metabolic disorders and paraneoplastic. Recent
studies have increased understanding of the range of cerebellar disorders associated with
a systemic immunological condition. The identification of newer pathogenic antibodies
has improved diagnosis in conditions which would have previously been labelled as
idiopathic. However, their rarity and phenotypic variability makes defining optimal
immunomodulatory treatment regimens challenging. There is some evidence for beneficial
effects of immunomodulation, particularly in anti-GAD ataxia and Hashimoto’s encepha-
lopathy, although, at this time, specific treatment regimens cannot be defined. Immune-
mediated paraneoplastic cerebellar disorders show response to therapy dependent, to
some extent, on the underlying pathogenic antibody. Much is still to be understood
concerning treatment regimens for the ataxic manifestations of metabolic disorders,
notably alcohol-induced cerebellar injury, which are common and which are associated
with significant disability.
Summary Despite their rarity, cerebellar ataxias occurring in the context of systemic
disease cause significant morbidity and better therapies are required to improve outcomes
associated with these conditions.
Introduction
Dysfunction of the cerebellum can occur either as a
result of localised injury or in the context of a number
of systemic diseases. Systemic disorders often affect the
central nervous system diffusely, but, in a number of
situations, may specifically cause cerebellar dysfunction.
Within this review, cerebellar ataxia in the context of
systemic diseases will be considered. Broadly, systemic
disorders affecting the cerebellum may be divided into
systemic immunological disorders, endocrine and met-
abolic disorders and paraneoplastic. While some of the
conditions discussed have no specific treatment, there
are emerging studies suggesting specific conditions may
respond to particular treatments.
Ataxia and systemic immunological disorders
Anti-GAD ataxia
Non-paraneoplastic autoimmune cerebellar ataxia was first defined some
20 years ago with the identification of antibodies, in both serum and CSF,
directed against the enzyme glutamic acid decarboxylase (GAD) [1]. Since the
earliest reports, a strong association between anti-GAD and systemic autoim-
mune conditions has been confirmed, including type 1 diabetes, pernicious
anaemia, vitiligo and thyroiditis [2]. Yet, the cerebellum should in itself be
considered a primary target organ for autoimmunity, as evidenced by the high
proportion of HLA type DQ2 and the demonstration of cerebellar antibodies in
some 60% of patients with otherwise idiopathic ataxia [3]. The cerebellum
therefore, alongside the hippocampus, appears particularly vulnerable to
immune-mediated pathology—mechanistic evidence is strongest for the
GAD65 isoform, probably via (reversible) interference in GABA exocytosis
(reviewed in [4•]) but also resulting in (irreversible) Purkinje cell loss [5].
Anti-GAD disease may present clinically with either sub-acute or chronic ataxia,
potentially accompanied by features of overlapping neurological conditions
also attributed to anti-GAD, including stiff-person syndrome [6]. Therapeutic
approaches may therefore simultaneously need to target symptomatic relief of
muscle rigidity with GABAergic agonists such as diazepam [7]. A meaningful
impact on ataxic symptoms is less reliably achieved, although baclofen was
reportedly of benefit for periodic alternating nystagmus [8]. Outside the context
of anti-GAD disease, aminopyridines may relieve downbeat nystagmus [9]
while acetyl-DL-leucine shows promise among unselected ataxia cases [10]
but awaits placebo-controlled confirmation [11].
With the expectation that most patients with anti-GAD cerebellar ataxia will
accumulate significant disability [12], consideration is often given to immuno-
suppression despite the lack of evidence from placebo-controlled trials [13].
Overall, the reported results of treatment are mixed, with the largest case series
reporting ‘robust’ responses in a higher proportion of 55 non-paraneoplastic
cerebellar ataxia patients compared with 63 paraneoplastic cases [14••]. Over
half of the non-paraneoplastic cases in this series responded to immunothera-
py, typically including long-term maintenance. Long-term follow-up data has
also been reported for a further 25 ataxia patients with GAD65 antibodies in
whom 35% experienced an improvement of at least 1 point on the modified
Rankin Scale [15•]. Sub-acute presentations carried a more favourable progno-
sis than chronic ataxia. Varying induction regimes combining steroids,
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intravenous immunoglobulins (IVIg) and plasma exchange (PEx) have been
utilised, typically relying on clinical status to assess response, although neuro-
physiological outcome markers may also inform [16]. While decreases in
serum, anti-GAD levels have often tracked effective therapy, for example with
rituximab [17], intrathecal levels may be more reflective of treatment response
[18]. Further uncertainty surrounds cases of cerebellar ataxia with low (G 100U/
ml) serum titres of anti-GAD, in whom responses to immunotherapy are
sparsely described [19, 20]. Antibodies against the GAD67 epitope may poten-
tially also be pathogenic [21]. Evidence-based recommendations for mainte-
nance therapy are not currently possible but previous choices have included
azathioprine and mycophenolate (discussed in [22]).
Gluten ataxia
Anti-GAD antibodies have also been detected in 40% of a well-defined cerebel-
lar ataxia cohort curated in Sheffield, UK [23]. These patients, however, had an
existing diagnosis of gluten ataxia suggesting therefore an overlapping spectrum
of cerebellar autoimmunity. This neurological syndrome is infrequently the
presenting clinical feature of coeliac disease, antibodies to gliadin and/or
transglutaminase are accordingly detectable in between 10 and 50%of sporadic
ataxia patients, depending on the background population [24]. Coeliac disease
is also held responsible for cases of peripheral neuropathy [25] and other
diverse neurological manifestations, yet, not all gluten ataxia patients have
biopsy evidence of enteropathy and few have gastrointestinal symptoms; con-
versely 37% of newly diagnosed coeliac patients exhibit neurological signs in
one report [26].
While randomised trial data concerning treatment of gluten ataxia is lacking,
the broader necessity for systemic control of coeliac disease applies equally to
this subgroup [27]. Strict adherence to a gluten-free diet is therefore recom-
mended. A single pragmatically designed study investigated the impact on
gluten ataxia on 26 patients who adhered to the diet compared at baseline to
14 patients who declined the intervention [28]. Diet-compliant patients, re-
gardless of whether enteropathy was initially detectable, showed significant
improvement across a range of ataxia clinical measures. Further mechanistic
evidence in support of gluten avoidance is provided by a recent MR spectros-
copy study in which a normalisation of NAA/Cr ratio in the cerebellar vermis
resulted from successful diet adherence (as indexed by elimination of detectable
anti-gliadin antibodies); the effect was diminished by partial adherence [29].
Symptomatic improvement is typically delayed by approximately 1 year and
ataxia may only stabilise in advanced cases with established cerebellar atrophy.
Whether incremental benefit is likely with simultaneous immunosuppression
remains to be determined; isolated reports describe clinical improvement with
IVIg [30], even among cases refractory to gluten-free diet [31].
Ataxia and systemic endocrine/metabolic disorders
Alcohol-induced cerebellar disease
Chronic excessive alcohol ingestion is a common cause of cerebellar degener-
ation. Clinically, patients present with ataxia predominantly affecting legs and
gait, and typically occurs in association with features of malnutrition. Some
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patients may present acutely with Wernicke encephalopathy (WE), which has
the added features of delirium, cognitive impairment and oculomotor deficits.
The association of WE and thiamine (vitamin B1) deficiency is well-recognised;
however, it remains unclear to what extent chronic alcohol-induced cerebellar
damage is caused by the effects of thiamine deficiency or directly attributable to
the toxic effects of alcohol on the brain [32]. Abstinence from alcohol and
thiamine supplementation remains the mainstay of treatment.
Abstinence from alcohol was also shown to result in clinically relevant
improvement in chronic alcoholic cerebellar degeneration, as assessed by
measures of postural instability over 18 months [33]. A further study (over
2 years) confirmed that abstinence can improve postural stability andmay be
linked to changes in fourth ventricular size [34]. Perhaps not surprisingly,
long-term abstinence (9 18 months) is associated with better recovery of gait
and balance problems above and beyond short-term abstinence (6–
15 weeks) [35].
Regarding thiamine replacement, its role in WE is established. However, a
recent Cochrane review only found two randomised trials and no firm conclu-
sion regarding the dose, route of administration and minimum duration for
treatment or prophylaxis against WE could be made [36••]. In practice, due to
unreliable absorption of thiamine inmalnourished patients, it is recommended
that thiamine is administered intravenously in acute WE, although only class IV
evidence exists to back up this guidance [37]. Whether thiamine replacement is
of benefit in chronic alcoholic ataxia is unknown, but typically, patients are
prescribed with vitamin supplementation. The fact that WE can occur in the
setting of poor nutrition unrelated to alcoholism suggests that thiamine re-
placement is likely to be of benefit in patients who have become abstinent,
although evidence is lacking. There is no evidence that thiamine replacement is
effective in improving ataxia in those with established chronic alcoholic cere-
bellar degeneration.
Thyroid disease and ataxia
Ataxia has been reported in hypothyroidism [38]. However, whether a lack of
thyroid hormone genuinely causes cerebellar dysfunction is not clear. Hypo-
thyroidism is common and the rarity of ataxia in the condition may suggest a
lack of causality and possibly coincidence of separate diseases [39]. Gait prob-
lems in hypothyroidism may often be attributed to the typical changes in
muscle contractility that occurs. Treatment with thyroxine is routine and typi-
cally improves systemic features of the disease.
Hashimoto’s encephalopathy (HE) is a neurological condition associated
with elevated anti-thyroid antibodies (anti-thyroglobulin or anti-thyroid
peroxidase (TPO)), often occurring in euthyroid individuals [40]. Since
anti-TPO antibodies can occur in the healthy general population, the diag-
nosis may be challenging. Antibodies against NH2-terminal of α-enolase
(NAE) have been reported as a useful serum biomarker of HE [41]. Reports
have suggested that HE may rarely present as an isolated ataxic syndrome. A
case series of 13 adult patients (of whom eight had anti-NAE antibodies)
with a predominantly ataxic form of HE reported that truncal ataxia is
common and nystagmus is uncommon, and eight out of 13 had a syndrome
mimicking spinocerebellar degeneration with insidious onset [42]. One of
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the cardinal features of HE is its responsiveness to immunotherapy (hence,
the alternative nomenclature of steroid-responsive encephalopathy associat-
ed with autoimmune thyroiditis [SREAT]). A recent study of 13 patients with
anti-NAE HE reported full or good recovery in 11 patients treated with
methylprednisolone with or without prednisolone tail (one patient also
received plasma exchange) [43]. In the case series of ataxic HE mentioned
above, all patients responded to steroid treatment and/or IVIg [42]. Response
appeared better in those with anti-NAE antibodies although the study size
was small. Despite the usually good response to steroid therapy, relapse after
steroid withdrawal may occur and optimal maintenance therapy is not clear.
There is no trial evidence but reports have described use of azathioprine,
mycophenolate mofetil, methotrexate, cyclophosphamide, rituximab, main-
tenance IVIg and plasma exchange [44–46].
Paraneoplastic ataxic manifestations
Paraneoplastic syndromes within the central nervous system (CNS) refer to
non-metastatic involvement of the brain and/or spinal cord, most likely occur-
ring as a result of an immune reaction to cancer cells generating antibodies
which cross-react with CNS antigens [47]. They occur rarely, but of the described
CNS paraneoplastic syndromes, paraneoplastic cerebellar degeneration (PCD)
is the commonest.
Paraneoplastic cerebellar degeneration
Fifty to 60% of patients with paraneoplastic cerebellar degeneration (PCD)
have identifiable antibodies in serum and/or CSF, of which anti-Yo (alterna-
tively referred to as anti-Purkinje cell cytoplasmic antibody-1; PCA-1) is the
commonest, representing approximately 50% of antibody-positive PCD [48].
PCD typically presents with sub-acute onset of ataxia which, often rapidly,
progresses to pan-cerebellar failure. Often, cerebellar features plateau after a
period of time. PCD may occur as an isolated cerebellar syndrome usually
associated with breast or ovarian cancer and anti-Yo antibodies, or with
Hodgkin’s lymphoma and Tr/DNER antibodies [49]. Alternatively, PCD pre-
sents in association with other neurological features such as encephalomyelitis
(small cell lung cancer and anti-Hu antibodies) [50] or eye movement abnor-
malities (typically, opsoclonus with breast or ovarian cancer and anti-Ri anti-
bodies) [51]. The repertoire of antibodies associated with PCD is increasing,
now including antibodies against the Purkinje cell protein carbonic anhydrase-
related protein VIII (CARP) [52] and protein kinase Cγ (PKCγ) [53]. It seems
likely that further antibodies will be discovered identifying a cause in antibody-
negative PCD cases.
In general, PCD responds poorly to treatment. The rarity of the condition,
coupled to the multiple antibodies that may cause the phenotype, has meant
that randomised controlled trials of PCD therapies are lacking. In addition, the
rather rapid disease onset followed by plateau renders determination of treat-
ment efficacy challenging.
Treatment or removal of the underlying tumour, if possible, is im-
portant, although even if successful, often, the symptoms of PCD do not
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improve and the majority of patients with PCD will remain severely
disabled [50, 54]. Prognosis is poor and median survival in a study of
34 anti-Yo PCD cases was 22 months [54]. Studies have suggested that
prognosis may be slightly better in PCD associated with antibodies other
than anti-Yo [55]. Indeed, improvement in PCD associated with anti-Tr
antibodies and Hodgkin’s lymphoma has been reported following treat-
ment of the cancer [56].
Studies have assessed the utility of additional immunotherapy in PCD. The
outcomes are generally disappointing although some small case series have
reported benefit (class IV evidence). Immunotherapies such as corticosteroids,
IVIg and PEx have been most studied. PEx has been reported to cause improve-
ment in some cases, although the majority of reported cases do not appear to
improve [57]. Similarly, IVIg has been reported to be effective in single cases,
although a study of 22 patients with anti-neuronal antibody-associated
paraneoplastic neurological syndromes (including 4 with PCD) did not reveal
any effect on disability using IVIg (median 5.8 cycles) [58–62]. The most
commonly reported alternative immunosuppressant is cyclophosphamide,
but, again, evidence is limited only to single cases [63, 64]. Aggressive combi-
nation immunosuppressive regimes have been reported [65]. A follow-up study
of 17 patients with anti-Yo and anti-Hu paraneoplastic encephalomyelitis,
sensory neuropathy or PCD receiving cycles of IVIg, cyclophosphamide and
methyl prednisolone reported clinical stabilisation (evaluated by the modified
Rankin scale) in those patients who were not severely disabled at time of
treatment onset, but no effect in severely disabled PCD patients [66]. It remains
unclear whether early administration of immunosuppression in PCD improves
prognosis.
Newer therapies including tacrolimus and rituximab have been studied in
case reports or small case series in PCD. Rituximab has been reported to induce
partial remission in individual cases [67–69]. Tacrolimus, a potent T cell
inhibitor, has been studied in a series of patients with paraneoplastic neurolog-
ical disease (including PCD) [70]. Although, the trial was not designed to
quantify neurological outcome, there were anecdotal reports in some patients
of improvement in function. More studies are required to determine the influ-
ence of immunosuppressive regimes on PCD.
Conclusion
There is some evidence concerning treatment regimens for cerebellar
ataxias occurring in the context of systemic disease. Cerebellar ataxia
occurring in the context of a systemic immunological disorder is often
amenable to a range of immunomodulatory therapies, although the
rarity of these disorders and the phenotypic variability makes defining
optimal treatment regimens challenging. The commoner ataxic manifes-
tations of metabolic disorders, notably alcohol-induced cerebellar injury,
have been the subject of several studies, although there is a paucity of
evidence concerning optimal treatments for chronic alcoholic cerebellar
degeneration. Despite their rarity, cerebellar ataxias occurring in the
context of systemic disease cause significant morbidity and better thera-
pies are required to improve outcomes associated with these conditions.
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